Engflag

Prolopa 250

Quick links to important sections

Prolopa 250

Prolopa 250_EN

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Prolopa 250

Property Description
Active ingredient Levodopa and Benserazide
Form Oral capsule or tablet (including dispersible and modified-release options)
Pharmacological class Antiparkinsonian Agent
Common use Management of motor symptoms in Parkinson's disease
Origin Synthetic, fixed-dose combination

What Type of Medicine is Prolopa 250?

Prolopa 250 is a prescription-only, synthetic medication classified as an antiparkinsonian agent, utilized to help manage the chemical deficiency linked to movement disorders. It is administered via the oral route in the form of capsules or tablets.

The medication is formally known by its active ingredients, Levodopa/Benserazide. This formulation is consistently recognized for its efficacy in addressing the central deficit of dopamine, a neurotransmitter vital for motor control. The combination strategy itself is a clinically validated approach for optimizing substance delivery to the central nervous system.

Active Ingredients and Drug Formulation

Prolopa 250 is a precise combination of Levodopa (the dopamine precursor) and Benserazide (a peripheral DOPA decarboxylase inhibitor). The Levodopa component is the substance required for brain function, while the Benserazide component is intended to act as a chemical barrier in the body’s circulation.

This design prevents the premature breakdown of Levodopa outside the brain, a mechanism that pharmacological studies confirm significantly increases the therapeutic availability of the precursor substance. The inclusion of the inhibitor ensures that the majority of Levodopa is preserved for conversion into functional dopamine once it reaches the central nervous system.

The General Purpose of Levodopa/Benserazide

The general purpose of the Levodopa/Benserazide combination is to help correct the fundamental deficit of dopamine signaling in the brain that characterizes Parkinson's disease. By restoring the balance of chemical messengers, the medication assists the patient in regaining better control over motor function.

This targeted action of replenishing the deficient neurotransmitter is typically used for the management of core motor symptoms, such as rigidity, tremor, and slowness of movement. This established therapeutic approach is supported by decades of clinical use, demonstrating its foundational role in assisting patients with the daily maintenance of motor control.

Regulatory References

  1. NIH: Levodopa/Carbidopa Review
  2. Prolopa 250
  3. antiparkinsonian agent

What side effects are possible with Prolopa 250?

Possible Side Effects and Safety Information

The official regulatory safety documentation for Prolopa 250 (Levodopa/Benserazide) structures its risk profile based on formal classifications and limitations. The adverse reactions are categorized by frequency and the body systems they affect, according to authoritative government sources like the EMA and FDA.

Adverse Reaction Classifications

Side effects are grouped by their likelihood of occurrence, ranging from common to rare. Common reactions often involve the nervous system, such as involuntary movements (dyskinesia), and gastrointestinal symptoms like nausea and vomiting, particularly upon initiating treatment. Changes in blood pressure, such as orthostatic hypotension, are also commonly documented.

Less frequent, or uncommon, reactions include disturbances in heart rhythm (cardiac arrhythmia) and certain psychotic disorders. Rare effects encompass serious disorders of the blood and lymphatic system, such as haemolytic anaemia.

Serious Safety Considerations

The regulatory profile identifies certain reactions as clinically significant. These include the development of Impulse Control Disorders (ICDs), episodes of sudden onset of sleep that may occur without warning, and severe psychiatric changes. The product information also details specific situations where the medicine should not be used (contraindications).

Safety Restrictions: The medicine is formally contraindicated in individuals with severe uncompensated endocrine, renal, or hepatic impairment. It must also not be used concurrently with non-selective Monoamine Oxidase Inhibitors (MAOIs) or in patients with certain conditions like narrow-angle glaucoma or a history of melanoma. These restrictions define the formal regulatory boundaries for its use.

Overdose and Emergency Response

Overdose and When to Seek Help

Immediate actions and when to seek urgent help:

Upon confirmed or suspected over-ingestion of Prolopa 250, regulatory guidance mandates that you contact a doctor, nurse, pharmacist, hospital emergency department, or regional Poison Control Centre immediately.

This urgent action is required regardless of whether noticeable symptoms are present, due to the potential for severe, delayed physiological effects.

Documented Overdose Manifestations

Officially documented clinical signs of overdose stem from excessive dopaminergic activity. These manifestations affect both the central nervous system and the cardiovascular system.

Central nervous system effects listed in regulatory documents include mental confusion, hallucinations, psychomotor agitation, insomnia, and abnormal involuntary movements such as spasms or twitching.

Cardiovascular signs listed are tachycardia (rapid or uneven heart beat), palpitations, and significant fluctuations in blood pressure, including hypotension (low blood pressure) and hemodynamic instability.

Management and Monitoring Requirements

Regulatory authorities state that no specific antidote is known for Levodopa/Benserazide poisoning. Consequently, the required management is based on symptomatic and supportive treatment to address the specific manifestations. Due to the cardiovascular risks, mandatory cardiac function monitoring is explicitly required during the management of an overdose event. The use of this medication is officially contraindicated in patients under 25 years old, a population-specific risk noted in the labeling.

Connection to the Overall Overdose Profile

Official regulatory documents define the overdose profile by listing severe cardiovascular and central nervous system symptoms that necessitate immediate, non-negotiable professional medical intervention. The documented need for supportive management and cardiac monitoring under all overdose circumstances frames the emergency help-seeking conditions.

Therapeutic Uses of Prolopa 250

What Prolopa 250 Treats: Main Uses and Benefits

This medication is applied across therapeutic domains involving certain distressing symptoms of movement disorders. The core use is within therapeutic areas involving certain distressing symptoms of Parkinson's disease. It is relevant for easing symptoms that interfere with daily functioning, including the slowness of movement (bradykinesia), muscle stiffness (rigidity), and involuntary shaking (tremor), and provides support that helps ease the overall symptom load.

In specific clinical scenarios, it is also applied when additional management of discomfort is required for severe Restless Legs Syndrome (RLS). Its application is relevant when supportive symptom management is appropriate, assisting with symptomatic relief during phases when symptoms become more noticeable. This supportive approach may help patients cope more steadily with symptom fluctuations, assisting with maintaining functional stability and contributing to improved day-to-day comfort.

“This medication is commonly used when symptoms create noticeable functional strain, and helps to ease the overall symptom load.”

Quick Fact: Support for Motor Symptoms This treatment is applied in clinical settings that involve acute or unstable symptom patterns, primarily assisting with easing the physical manifestations that affect mobility and control.

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Prolopa 250

This section outlines the official eligibility and non-eligibility requirements for Prolopa (levodopa/benserazide) as mandated by governmental health regulatory authorities.

Contraindicated Populations (Must Not Use)

Classification Exclusion Criteria (As Stated in Regulatory Labels)
Allergy Known hypersensitivity to levodopa, benserazide, or any excipients.
Co-Medication Concomitant use with non-selective MAO inhibitors (or within 2 weeks of withdrawal).
Life Stage Pregnant women or women of childbearing potential not using adequate contraception; Breastfeeding mothers; Patients under 25 years old (skeletal development incomplete).
Comorbidities Narrow-angle glaucoma; Psychiatric diseases with a psychotic component; History of malignant melanoma or suspicious, undiagnosed skin lesions.
Organ Function Severe, decompensated endocrine, renal, hepatic, or cardiac disorders.

Conditional Use (Requires Special Consideration/Monitoring)

Use is allowed but requires caution, monitoring, or dose adjustment for individuals with: Open-angle glaucoma (regular intraocular pressure checks advisable); history of myocardial infarction or cardiac arrhythmia (cardiac monitoring required); peptic ulcer disease history; or diabetes (frequent blood sugar monitoring required).

Eligibility Summary

The official eligibility profile is structured around these absolute exclusions and specific cautionary measures. Individuals who are free from the listed contraindications and meet the adult age requirement (typically 25 years or older) are considered eligible for treatment, provided any conditional uses are managed with the required monitoring as described in the official product information.

What should I know about interactions with other medicines?

Prolopa 250 Interactions with other medicines and products

Official regulatory documents define specific medicinal product interactions and substance constraints for Levodopa/Benserazide (Prolopa 250).

Contraindicated and High-Risk Combinations

  • Non-selective Monoamine Oxidase Inhibitors (MAOIs): Co-administration is formally contraindicated due to the high risk of hypertensive crisis, necessitating a mandatory 14-day washout period before initiating therapy.
  • Halothane: The medication must be discontinued 12–48 hours before general anesthesia with Halothane due to the documented risk of blood pressure fluctuations.
  • Sympathomimetic Amines: Use requires caution, as their cardiovascular effects may be potentiated.

Pharmacodynamic and Exposure-Modifying Interactions

  • Antipsychotic Drugs (D2-Antagonists): May reduce the clinical effectiveness of the medication via pharmacodynamic antagonism.
  • Antihypertensive Drugs: Carry a risk of symptomatic postural hypotension due to additive effects.
  • COMT Inhibitors: Increase Levodopa exposure (AUC/bioavailability) by inhibiting its enzymatic clearance pathway.
  • Iron Salts: Can reduce the absorption and bioavailability of Levodopa due to a chelation mechanism, requiring timing separation.

Food, Alcohol, and Substance Constraints

  • High-Protein Food: Reduces absorption via documented Large Neutral Amino Acid (LNAA) transport competition and requires separation from doses.
  • Alcohol (Ethanol): May increase nervous system side effects and carries a documented risk of dose dumping with the extended-release formulation.

Mechanism of Action

Prolopa 250 is a fixed-dose combination product containing the dopamine precursor levodopa and the peripheral decarboxylase inhibitor benserazide. Its action involves dual mechanistic pathways targeted at enhancing central dopaminergic signaling.

Peripheral Action

Benserazide does not cross the blood-brain barrier (BBB). Its primary action is a competitive inhibition of the peripheral enzyme aromatic L-amino acid decarboxylase (AADC). AADC is responsible for the conversion of levodopa to the neurotransmitter dopamine in extracerebral tissues, such as the gastrointestinal tract and liver. Benserazide's inhibition of AADC significantly reduces peripheral levodopa catabolism, thereby increasing the fraction of the administered levodopa dose available to cross the BBB via the L-type amino acid transporter.

Central Action

Upon crossing the BBB, the elevated systemic concentration of levodopa enters dopaminergic neurons in the central nervous system. Inside these neurons, levodopa serves as a substrate for the remaining, uninhibited central AADC, resulting in its decarboxylation to dopamine. This process replenishes central dopamine stores. The newly synthesized dopamine is then released into the synaptic cleft, where it functions as an agonist, binding to and activating postsynaptic Dopamine receptors (D1 to D5 families). The systemic physiological consequence is a modulation of motor control circuits that are regulated by central dopaminergic activity.

Dosage and Administration Information

Official Administration Guidelines for Prolopa (Levodopa/Benserazide)

This section outlines the regulatory-approved instructions for the use of Levodopa/Benserazide, which is administered orally in divided daily doses.

Dosing and Administration Schedule

Administration Aspect Regulatory Instruction
Route Oral administration only.
Initial Adult Dose Typically begins with 50 mg/12.5 mg three or four times daily, or 100 mg/25 mg three times daily in advanced disease.
Titration and Frequency The dose is gradually increased, or titrated, often by one 100 mg/25 mg equivalent, at weekly intervals until the individual maintenance dosage is reached. The total dose must be divided into multiple portions per day.
Maximum Dose It is rarely necessary to administer more than 1,000 mg/250 mg (levodopa/benserazide) per day.

Procedural Requirements

Timing in Relation to Meals

  • Standard and dispersible forms should be taken at least 30 minutes before or 1 hour after a meal. This timing is intended to avoid interference from dietary protein on the medicine's absorption. Taking the dose with a low-protein snack or liquid may be advised during the initial treatment phase to help with tolerance.

Preparation and Handling

  • Dispersible tablets must be dissolved in a small amount of liquid, such as a quarter of a glass of water or fruit squash, and consumed within half an hour of preparation.
  • Modified-release capsules must be swallowed whole and must not be crushed, broken, or chewed.

Age-Specific Rules

  • Use is not recommended for patients under 25 years of age.
  • In older patients, treatment may be initiated with a lower dose and the increase in dosage should be slower, occurring every third or fourth day.

Switching Therapy

  • If transferring from levodopa-alone therapy, the previous treatment must be discontinued for at least 12 hours before starting Levodopa/Benserazide.

Recent Clinical Evidence

Recent Clinical Evidence

Overview of Carbidopa-Levodopa Research

Prolopa 250 is a combination formulation containing carbidopa and levodopa. Levodopa remains the cornerstone medication for managing the motor symptoms of Parkinson's disease (PD). Research consistently focuses on optimizing its delivery and efficacy, particularly in managing fluctuations in motor response, commonly referred to as 'wearing-off' periods.

Studies confirm that levodopa helps replenish dopamine levels in the brain, mitigating symptoms like rigidity, tremor, and bradykinesia. Carbidopa is essential as it inhibits the peripheral breakdown of levodopa, allowing a greater amount to cross the blood-brain barrier.

Pharmacokinetic Advancements

Recent clinical trials have explored methods to provide more sustained therapeutic plasma concentrations of levodopa to address motor complications. Traditional oral tablets, such as Prolopa 250, provide pulsed dosing, which is effective initially but can contribute to the development of motor fluctuations over time. Newer formulations and delivery systems aim to mimic continuous dopaminergic stimulation (CDS).

Research has specifically tracked the following parameters related to carbidopa-levodopa formulations:

  • 'On' Time: The total daily duration when a patient experiences good motor function.
  • 'Off' Time: The total daily duration when motor symptoms return (e.g., tremor, stiffness).
  • Dyskinesia: Involuntary, erratic movements that can be a side effect of long-term pulsatile levodopa therapy.

Safety and Long-Term Use

Clinical evidence consistently supports the combination's long-term risk/benefit profile in PD management. Key safety monitoring focuses on gastrointestinal side effects (nausea, vomiting), orthostatic hypotension, and neuropsychiatric disturbances (hallucinations, confusion). The long-term use of levodopa can be associated with dyskinesia, which is tracked as a primary endpoint in many ongoing clinical studies comparing standard tablets to modified-release or continuous-delivery systems.

Frequently Asked Questions (FAQ)

Common questions about Prolopa 250 (FAQ)

Q: What does the '250' mean on my Prolopa 250 mg / 62.5 mg tablet?

The number 250 mg refers to the amount of levodopa present in the tablet. Prolopa is a combination medicine, and this number specifically indicates the quantity of the primary active ingredient. Official documents describe the formulation as containing levodopa along with benserazide.

Q: Do I need to avoid any vitamins while taking this medication?

Official product information notes that certain supplements may interact with this medicine. Regulatory labels state that iron supplements and high doses of Vitamin B6 (pyridoxine) may reduce the absorption or affect the action of the medicine.

Q: Why do some people experience dyskinesia (uncontrolled movements) after taking levodopa for a long time?

Involuntary movements, known as dyskinesia, are a commonly documented side effect of long-term levodopa treatment. Regulatory documents indicate that managing this effect may involve a review of the dosage by a healthcare professional.

Q: Is a generic version of Prolopa available?

Yes, the official active ingredients of Prolopa—levodopa and benserazide—are often available under various generic names in many global regions. Regulatory bodies have authorized generic products containing the same active ingredients.

Q: Can I drive while taking Prolopa?

Official safety information for this medicine highlights that it can cause drowsiness and, in some cases, sudden episodes of sleep without warning. Regulatory guidelines specify that if a patient experiences these effects, they are advised to refrain from driving or operating machinery.

Q: Can Prolopa cause vivid dreams or hallucinations?

Yes, the official adverse reaction profile for the medicine includes the possibility of vivid dreams, insomnia, and hallucinations. These effects are described as potential psychiatric side effects, particularly in sensitive individuals.

Q: What happens if I stop taking Prolopa suddenly?

Regulatory warnings indicate that abrupt cessation of this medicine is not recommended. Suddenly stopping can lead to a condition that shares features with neuroleptic malignant syndrome, which is characterized by symptoms such as high fever, severe muscle stiffness, and mental changes.

Q: How long does it take for Prolopa to start working after I take a dose?

Pharmacokinetic data shows that the concentration of the active ingredient in the blood typically reaches its peak about one to two hours after taking a standard oral dose. However, the time it takes to notice a clinical effect can vary significantly between individuals.

Q: Is Prolopa a cure for Parkinson's disease?

No, official regulatory documentation defines this medicine as a treatment for the symptoms of Parkinson's disease. Its purpose is to help restore a chemical balance in the brain; it does not offer a cure for the underlying condition.

Q: What should I do if I miss a dose?

The official patient information leaflet generally states that if a dose is missed, patients should take it when remembered. The leaflet also cautions that a double dose should not be taken to make up for a missed dose.

Q: Does Prolopa affect any of my lab tests?

Yes, official safety information indicates that this medication may interfere with the results of certain clinical laboratory tests. This interference may include tests for substances such as catecholamines, creatinine, and uric acid.

Q: Can Prolopa be used for Restless Legs Syndrome (RLS)?

The only condition for which this medicine is officially indicated and authorized by regulatory bodies is the treatment of Parkinson's disease. The official product information does not list Restless Legs Syndrome as an approved use.

Q: Is Prolopa effective for non-motor symptoms of Parkinson's, like mood and cognition?

The medicine is primarily designed and indicated for improving the motor symptoms of Parkinson's disease, such as tremor and rigidity. However, psychiatric adverse effects like depression and anxiety are listed in the official product information.

Q: Is Prolopa recommended for early-stage Parkinson's?

Official guidelines indicate that treatment is typically initiated at a low dosage and then gradually increased to meet the patient’s individual needs. This careful approach applies to the initiation of therapy.

Q: Can Prolopa cause changes in my appetite or weight?

Official documentation lists changes in appetite and weight as possible adverse reactions. Reported effects include decreased appetite, loss of appetite, and changes in body weight.

How should Prolopa 250 be stored and disposed of?

Official Storage Conditions

Storage of Prolopa 250 (Levodopa/Benserazide) must follow specific requirements defined by regulatory authorities to ensure product stability:

  • Maximum Temperature: The product must not be stored at temperatures above 25 C (77 F).
  • Environmental Protection: The container must be kept tightly closed to protect the medication from moisture, which is necessary for maintaining its stability.
  • Packaging: The medicine should be stored in its original package until use.
  • Child Safety: For safety, the product must be kept out of the sight and reach of children.

Official Disposal Instructions

Disposal protocols are regulated to prevent environmental contamination:

  • General Rule: Unused or expired Prolopa 250 must be disposed of in accordance with local regulatory requirements for pharmaceutical waste.
  • Prohibited Disposal: The product should not be discarded through household wastewater or refuse, but typically returned to a pharmacist or designated collection point.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Prolopa 250 found in:

A-Z Index: